From Yahoo Finance: 2025-03-19 16:56:00

Gilead Sciences stock fell 2.52% in premarket trading following reports of potential federal funding cuts for HIV prevention. The company produces medication for HIV and AIDS treatment, causing concern among investors. The US Health and Human Services Department is considering significant funding reductions, impacting biopharma firms like Gilead and GSK. The CDC’s budget cuts could affect drugmakers combating HIV.



Read more at Yahoo Finance: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention